These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 7833220)
1. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Cockcroft JR; Chowienczyk PJ; Brett SE; Bender N; Ritter JM Br J Clin Pharmacol; 1994 Oct; 38(4):317-21. PubMed ID: 7833220 [TBL] [Abstract][Full Text] [Related]
2. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Witherow FN; Helmy A; Webb DJ; Fox KA; Newby DE Circulation; 2001 Oct; 104(18):2177-81. PubMed ID: 11684627 [TBL] [Abstract][Full Text] [Related]
3. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. Cockcroft JR; Sciberras DG; Goldberg MR; Ritter JM J Cardiovasc Pharmacol; 1993 Oct; 22(4):579-84. PubMed ID: 7505360 [TBL] [Abstract][Full Text] [Related]
4. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Brown NJ; Gainer JV; Murphey LJ; Vaughan DE Circulation; 2000 Oct; 102(18):2190-6. PubMed ID: 11056091 [TBL] [Abstract][Full Text] [Related]
5. Effect of NG-monomethyl-L-arginine on kinin-induced vasodilation in the human forearm. Cockcroft JR; Chowienczyk PJ; Brett SE; Ritter JM Br J Clin Pharmacol; 1994 Oct; 38(4):307-10. PubMed ID: 7530473 [TBL] [Abstract][Full Text] [Related]
6. Mediation by bradykinin of rat paw oedema induced by collagenase from Clostridium histolyticum. Legat FJ; Griesbacher T; Lembeck F Br J Pharmacol; 1994 Jun; 112(2):453-60. PubMed ID: 7915609 [TBL] [Abstract][Full Text] [Related]
7. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism. Hornig B; Kohler C; Schlink D; Tatge H; Drexler H Hypertension; 2003 May; 41(5):1092-5. PubMed ID: 12654707 [TBL] [Abstract][Full Text] [Related]
8. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. Gainer JV; Morrow JD; Loveland A; King DJ; Brown NJ N Engl J Med; 1998 Oct; 339(18):1285-92. PubMed ID: 9791144 [TBL] [Abstract][Full Text] [Related]
9. Direct biochemical evidence for eNOS stimulation by bradykinin in the human forearm vasculature. Lauer T; Kleinbongard P; Preik M; Rauch BH; Deussen A; Feelisch M; Strauer BE; Kelm M Basic Res Cardiol; 2003 Mar; 98(2):84-9. PubMed ID: 12607129 [TBL] [Abstract][Full Text] [Related]
10. Vascular B1 kinin receptors in patients with congestive heart failure. Lang NN; Cruden NL; Tse GH; Bloomfield P; Ludlam CA; Fox KA; Newby DE J Cardiovasc Pharmacol; 2008 Nov; 52(5):438-44. PubMed ID: 19033823 [TBL] [Abstract][Full Text] [Related]
11. Bradykinin B2-receptor antagonism attenuates fatal cardiocirculatory breakdown induced by severe experimental pancreatitis. Yekebas E; Treede H; Jochum M; Gippner-Steppert C; Bloechle C; Knoefel WT; Scholz J; Fink E; Izbicki JR Crit Care Med; 2000 Apr; 28(4):1119-27. PubMed ID: 10809293 [TBL] [Abstract][Full Text] [Related]
12. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Hornig B; Kohler C; Drexler H Circulation; 1997 Mar; 95(5):1115-8. PubMed ID: 9054837 [TBL] [Abstract][Full Text] [Related]
13. Effect of early blockade of bradykinin B2-receptors on the blood pressure phenotype of normotensive and spontaneously hypertensive rats. Emanueli C; Madeddu P Pharmacol Res; 1997 Jun; 35(6):522-6. PubMed ID: 9361315 [TBL] [Abstract][Full Text] [Related]
14. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515 [TBL] [Abstract][Full Text] [Related]
15. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Van Guilder GP; Pretorius M; Luther JM; Byrd JB; Hill K; Gainer JV; Brown NJ Hypertension; 2008 Feb; 51(2):454-9. PubMed ID: 18180402 [TBL] [Abstract][Full Text] [Related]
16. Role of kinins in the renal response to enalaprilat in normotensive and hypertensive rats. Fitzgibbon WR; Jaffa AA; Mayfield RK; Ploth DW Hypertension; 1996 Feb; 27(2):235-44. PubMed ID: 8567046 [TBL] [Abstract][Full Text] [Related]
17. Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Squire IB; O'Kane KP; Anderson N; Reid JL Hypertension; 2000 Jul; 36(1):132-6. PubMed ID: 10904025 [TBL] [Abstract][Full Text] [Related]
18. Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization. Honing ML; Smits P; Morrison PJ; Rabelink TJ Hypertension; 2000 Jun; 35(6):1314-8. PubMed ID: 10856283 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Pretorius M; Rosenbaum D; Vaughan DE; Brown NJ Circulation; 2003 Feb; 107(4):579-85. PubMed ID: 12566370 [TBL] [Abstract][Full Text] [Related]
20. Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes. Vora JP; Oyama TT; Thompson MM; Anderson S Diabetes; 1997 Jan; 46(1):107-12. PubMed ID: 8971089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]